- NCIt
- C40283
Loading cancer entity…
Loading cancer entity…
Clinical trials
57 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07793552 | Needlefree Lidocaine Application for Vulvar Biopsies | not yet recruiting | N/A | 106 | Tufts Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05463796 | InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | suspended | — | 55 | Wake Forest University Health SciencesOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06358469 | STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision(STRIVE) | recruiting | N/A | 249 | Canadian Cancer Trials GroupNETWORK | 2 | Aug 11, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04430699 | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | active not recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06075264 | Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)(ART-VIN IIB) | recruiting | Phase 2 | 27 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05104099 | Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia(PhotodiVIN) | completed | Phase 2 | 17 | Institut de Cancérologie de LorraineOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer | terminated | N/A | 409 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03061435 | Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.(Vulvar-AIN) | recruiting | N/A | 110 | Dr. Danielle VicusOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03267680 | IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06911801 | In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer(FAPI_VULVA_1) | not yet recruiting | — | 90 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05717621 | Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)(DelVIN) | completed | Phase 1 | 29 | ViMREX GmbHINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03792516 | Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)(ART-VIN) | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06297187 | Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study | completed | — | 56 | Integra LifeSciences CorporationINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | terminated | — | 20 | British Columbia Cancer AgencyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03051516 | HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions | terminated | Phase 4 | 188 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02735109 | Interest of the Confocal Microscope in the Diagnosis of Epidermoid Carcinoma of the Vulva and Their Precursors | terminated | N/A | 10 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02875561 | Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia | completed | N/A | 47 | University of Colorado, DenverOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03452332 | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | completed | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | completed | Phase 2 | 33 | Inovio PharmaceuticalsINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04952961 | Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study | completed | N/A | 25 | University of ManchesterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04761146 | A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer(DaRT-V) | unknown | N/A | 10 | CCTU- Cancer ThemeOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04704908 | Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) | unknown | — | 979 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04969445 | The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 647 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05045755 | The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 1,339 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05536843 | Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests(TTMV HPV DNA) | unknown | — | 500 | University of Mississippi Medical CenterOTHER | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05426148 | Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female | completed | Phase 4 | 540 | Xiamen Innovax Biotech Co., LtdINDUSTRY | 1 | Jun 29, 2022 | clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01595061 | Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva | unknown | Phase 2 | 57 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2021 | clinicaltrials |
| NCT01500512 | Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection(GROINSS-V) | unknown | — | 148 | Gynecologic Oncology GroupNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT01861535 | Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia(PITVIN) | completed | Phase 3 | 110 | Medical University of GrazOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03937791 | Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2021 | clinicaltrials |
| NCT01735006 | Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine | completed | Phase 3 | 7,372 | Xiamen UniversityOTHER | 1 | Feb 24, 2020 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials